About Callio Therapeutics
Callio Therapeutics is engineering dual-payload ADCs as the next frontier of targeted cancer therapy for patients with high unmet need tumors where better therapies are needed. Its proprietary platform pairs modular, adaptable linker technology with rationally selected synergistic payload combinations designed to block dominant resistance mechanisms that enable cancer’s escape.
Cancer’s Challenge
A large, underserved patient population that still lacks durable treatment.
While early-generation ADCs have transformed cancer care, they are still not curative. Most patients ultimately progress and are left with limited options, representing a significant unmet need for more durable treatments.
03
Limited by Early-Generation Design
Metastatic cancer remains largely incurable; early-generation ADCs are limited by insufficient potency, tolerability, and durability of response.
Callio Solution
A fundamentally different ADC strategy
Callio Therapeutics designs its ADCs to match payload combinations to tumor biology, mechanisms of resistance, and clinical context. Our systematic screening funnel robustly characterizes payload combination safety and efficacy to select the optimal pairing.
Rational Dual-Payload Biology
Callio Therapeutics designs with intent: matching payload combinations to tumor biology, mechanisms of resistance, and clinical context. Our systematic screening funnel robustly characterizes payload combination safety and efficacy to select the optimal pairing.
Proprietary Linker Platform
Callio Therapeutics’ proprietary linker technology enables precise, reproducible dual-payload ADC design. Site-specific conjugation yields a homogeneous, well-defined product, while the linker’s stability keeps both payloads attached until they reach the tumor, limiting free payload release and supporting favorable ADC pharmacokinetics.
Our Pipeline
Discovery Programs
Building a pipeline of differentiated dual-payload ADCs, enabled by a proprietary platform to target large cancer indications.
Our Team
Callio Therapeutics is built to deliver the next generation of dual-payload ADCs and better outcomes for people living with cancer.
Located in Seattle, San Diego, and Singapore, Callio Therapeutics is led by an experienced team with a track record of ADC development and oncology drug approvals.
Investors
Callio Therapeutics is supported by investors with a track record of creating and building high value oncology companies, providing the resources and strategic guidance to advance our dual-payload ADC pipeline.
News & Publications